secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056901
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Q1 net loss narrows to $31.8M; tab-cel BLA on track for Q2 2024 submission
--------------------------------------------------------------------------------

- Q1 2024 net loss of $31.8M ($0.23/sh) vs $74.8M ($0.72/sh) in Q1 2023; revenue rose to $27.4M from $1.2M on Pierre Fabre partnership.
- Cash, equivalents, ST investments $46.2M plus AR $35.8M; expects funding into 2027 with potential $80M in tab-cel BLA milestones.
- BLA submission for tab-cel in EBV+ PTLD planned Q2 2024; pivotal data showed 48.8% ORR (p<0.0001); Swissmedic approval received.
- ATA3219 lupus nephritis study to start Q4 2024; initial data H1 2025; new SLE cohort without lymphodepletion also in Q4 2024.
- Full-year 2024 operating expenses expected to decrease ~35% vs 2023; restructuring cut workforce by 25% to 170 employees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017024056901/0000950170-24-056901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017024056901/atra-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer